Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endometriosis
Biotech
Organon axes 'biggest potential opportunity' after trial fail
An endometriosis drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial.
Nick Paul Taylor
Jul 2, 2025 8:43am
Biden asks Congress for $12B to fund women's health research
Mar 8, 2024 10:25am
Organon builds pipeline for women's health but can't do it alone
Mar 16, 2023 11:12am
Bayer nixes midstage cough med weeks after Merck's was rejected
Feb 4, 2022 12:40pm
Organon buys Forendo in 3rd deal since spinning out of Merck
Nov 11, 2021 8:40am
Women's health-focused Celmatix snags Merck KGaA vet as CSO
May 26, 2021 10:28am
